Clinical Trial Update: Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating cetuximab plus capecitabine as maintenance therapy in metastatic colorectal cancer with wild-type RAS/BRAF; status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Cetuximab (cetuximab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer | Phase 3 | Status: UNKNOWN